张晓春 那彦群 韩文科 郭应禄 上海第二医科大学附属新华医院泌尿外科 200092 中华泌尿外科杂志 1999 0 20 11


    关键词：前列腺增生症；药物疗法；伯泌松 期刊 zhmnwkzz 0 论著 fur -->


    

【摘要】 目的 观察伯泌松治疗良性前列腺增生症(BPH)的有效性与安全性。 方法 全国45家医院529例BPH病人口服伯泌松3个月，用量为160mg，每天二次。 结果 口服伯泌松3个月后，病人前列腺症状评分(IPSS)减少37.5%，评分减少≥3分者占89.6%，最大尿流率从(11.1±7.8)ml/s增加到(14.9±7.8)ml/s，最大尿流率改善≥3ml/s的病人占56.5%；生活质量评分改善≥1分的病人占78.4%，前列腺体积平均减少9.1%；性生活也有所改善，膀胱剩余尿量减少43.5%。耐受性良好，服药过程中无血压下降。 结论 伯泌松治疗BPH安全、有效。

Permixon for the treatmentof benign prostatic hyperplasia

ZHANG Xiaochun,NA Yanqun,HANWenke,et al

    Depertment of Urology,the First Affiliated Hospital,Beijing Medical University,Beijing100034

【 Abstract】 Objective To study the clinicalefficacy of lipido-sterolic extract of Serenoa repens (Permixon) for benign prostatichyperplasia (BPH). Methods 529 BPH patients from 45 hospitals in China were evaluated before, during (4weeks) and after 3 months' treatment with 160mg Permixon twice a day. Results After 3 months of treatment, mean IPSS decreased by37.5%,89.6% of the patients with IPSS score being decreased more than 3.Qmax increasedfrom 11.1±7.8ml/s to 14.9±7.8ml/s,56.6% of the patients being more than 3ml/s. 78.4% ofthe patients had the QOL score improved more than 1.The mean reduction of prostate volumewas 9.1% and the residual urine decreased by 43.5%.An improvement of the sexual functionwas noted in the patients.All the changes were statistically significant.Tolerability ofthe medicine has been good with no drop of blood pressure. Conclusions 160mg Permixon twice a day is safe and effective for thetreatment of BPH.

     ......